Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

Amgen appoints Jonathan Graham general counsel and secretary

He will succeed David Scott who is retiring

- PMLiVE

Get Real! The Rise of Observational Data In Healthcare

Real world data is now becoming a serious research tool for pharma, but just what can it add to the golden standard that is the randomised clinical trial?

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

FDA panel backs Amgen’s T-Vec for melanoma

Approved by a panel of 22 to one despite questions on its impact on survival

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

- PMLiVE

FDA clears Amgen’s Corlaner for heart failure

It is the firm’s first cardiovascular product to gain approval

- PMLiVE

WHO calls for publication of previously unreported studies

Organisation claims results from clinical trials should be reported within 12 months

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links